1. Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma
- Author
-
Daanish Hoda, Robert Richards, Edward A Faber, Abhinav Deol, Bradley D Hunter, Elizabeth Weber, Heather DiFilippo, Toni Henderson-Clark, Linda Meaux, Concetta Crivera, Carrie Riccobono, Ashraf Garrett, Carolyn C Jackson, Jessica Fowler, Panteli Theocharous, Raj Stewart, Andrea L Lorden, David L Porter, and Ariel Berger
- Subjects
Cancer Research ,Receptors, Chimeric Antigen ,Oncology ,T-Lymphocytes ,Cell- and Tissue-Based Therapy ,Receptors, Antigen, T-Cell ,Humans ,General Medicine ,Multiple Myeloma ,Immunotherapy, Adoptive - Abstract
Patients with multiple myeloma can now be treated with chimeric antigen receptor T-cell (CAR-T) therapy. We studied how CAR-T therapy is used for multiple myeloma. We also studied things that could help make this therapy easier for doctors to use. The CAR-T process takes 13 steps and 177 days. It begins with the choice to use the therapy and ends about 100 days after it is used. The process uses 46 different healthcare professionals and ten different locations. We found several possible changes that can improve this process. Of these changes, three stand out. First, improved teamwork between members of the care team can help them prepare for and resolve possible problems. Second, reducing insurance red tape will make it easier to provide CAR-T therapy to patients. Third, allowing use of CAR-T therapy in places other than hospitals can help more patients receive this therapy. If applied, these three things may lower the time needed to treat patients by 14.4% and may reduce costs by 13.2%.
- Published
- 2022